| BioSig Enters into an LOI to Merge with Streamex Exchange Corp. |
Los Angeles, May 05, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company is pleased to announce it has entered into a Letter of Intent (“LOI”) to enter into a proposed merger or other business combination (the “Merger”), with Streamex Exchange Corporation (“Streamex”) in an all-stock transaction. |
globenewswire.com |
2025-05-05 13:42:00 |
Czytaj oryginał (ang.) |
| Biosig Technologies (BSGM) Upgraded to Buy: What Does It Mean for the Stock? |
Biosig Technologies (BSGM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-04-24 17:00:45 |
Czytaj oryginał (ang.) |
| BioSig Technologies Confirms Full Compliance with Nasdaq Requirements for Continued Listing on The Nasdaq Capital Market |
Los Angeles, CA, March 26, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, is pleased to announce that its common stock will continue trading on The Nasdaq Capital Market (“Nasdaq”). |
globenewswire.com |
2025-03-26 11:00:00 |
Czytaj oryginał (ang.) |
| BioSig Regains Compliance with Nasdaq's Minimum Bid Price Requirement |
Los Angeles, CA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or “Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced that it has received notice from the Nasdaq Listing Qualifications staff ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule"). |
globenewswire.com |
2024-11-13 17:14:00 |
Czytaj oryginał (ang.) |
| BioSig Technologies' Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel |
Los Angeles, CA, Oct. 22, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) (“BioSig” or the “Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced its successful appeal to the NASDAQ Panel, and as a result the Company's common stock will resume trading on the NASDAQ Capital Market Exchange at the open of trading on Wednesday, October 23, 2024. The Company was granted an extension until March 7, 2025, a 360-day grace period from the point at which the Market Value of Listed Securities (“MVLS”) requirement previously became non-compliant. |
globenewswire.com |
2024-10-22 19:13:00 |
Czytaj oryginał (ang.) |
| BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation |
Los Angeles, July 31, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) (“BioSig” or “Company”), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization for electrophysiology (EP) procedures, today announced the intent to acquire the assets of Neuro-Kinesis Corporation (NKC), a privately held Los Angeles-based medical technology company developing smart EP tools. |
globenewswire.com |
2024-07-31 13:45:00 |
Czytaj oryginał (ang.) |
| BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer |
Westport, CT, June 10, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Ferdinand Groenewald to the position of interim Chief Financial Officer. Personal Bio, Ferdinand Groenewald, age 39Ferdinand Groenewald is a certified public accountant with significant experience in finance and accounting. He currently serves as Vice President, Finance at Alaunos Therapeutics, Inc. Previously, Mr. Groenewald served as an Independent Outside Director at SYLA Technologies Co., Ltd.; an Independent Director at HeartCore Enterprises, Inc.; an Independent Director at Sushi Ginza Onodera, Inc.; an Accountant at Wrinkle, Gardner & Co. PC; a Senior Staff Accountant at Financial Consulting Strategies LLC; a Controller, VP-Finance & Accounting Officer at Sadot Group, Inc. and a Chief Financial Officer at the same company; and Chief Accounting Officer & VP-Finance at Muscle Maker Development LLC. Mr. Groenewald obtained an undergraduate degree from the University of South Africa. |
globenewswire.com |
2024-06-10 13:45:00 |
Czytaj oryginał (ang.) |
| BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules |
Westport, CT, May 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 1,570,683 shares of its common stock at a purchase price of $1.91 per share and concurrent private placement unregistered warrants to purchase up to 1,570,683 shares of common stock at an exercise price of $1.78 per share. The unregistered warrants are immediately exercisable and will expire five years from the date of issuance. |
globenewswire.com |
2024-05-30 20:05:00 |
Czytaj oryginał (ang.) |
| BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders |
Westport, CT, May 21, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or “Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, has today issued the following Letter to Shareholders: |
globenewswire.com |
2024-05-21 15:10:00 |
Czytaj oryginał (ang.) |
| BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent |
Westport, CT, May 03, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or "the Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced new appointments to its now fully constituted board of directors (the “Board”), which is comprised of a total of five (5) directors, three (3) of whom are classified as independent directors. The final compositions of the committees to the Board will be determined in the very near term. |
globenewswire.com |
2024-05-03 16:22:00 |
Czytaj oryginał (ang.) |
| BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately |
Westport, CT, April 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or "the Company"), a medical technology Company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Anthony Amato to the Position of Chief Executive Officer (“CEO”), effective immediately. |
globenewswire.com |
2024-04-30 18:03:00 |
Czytaj oryginał (ang.) |
| BioSig Engages Consulting Firm for Business Model Strategies |
BAIPC will work to deploy a series of solutions to transform BioSig's future course BAIPC will work to deploy a series of solutions to transform BioSig's future course |
globenewswire.com |
2024-04-04 15:35:00 |
Czytaj oryginał (ang.) |
| BioSig Announces Reduction of its Workforce |
Westport, CT, Feb. 20, 2024 (GLOBE NEWSWIRE) -- -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company, today announced that it has terminated a significant number of its employees and expects to substantially reduce business operations. |
globenewswire.com |
2024-02-20 12:00:00 |
Czytaj oryginał (ang.) |
| BioSig's PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases |
Company sees clinical adoption and usage of its novel Near Field Tracking algorithm, proven to reduce ablation time by approximately 66%. Company sees clinical adoption and usage of its novel Near Field Tracking algorithm, proven to reduce ablation time by approximately 66%. |
globenewswire.com |
2024-02-06 10:30:00 |
Czytaj oryginał (ang.) |
| BioSig Announces Reverse Stock Split |
Common Stock Will Begin Trading on Split-Adjusted Basis on February 2, 2024 Common Stock Will Begin Trading on Split-Adjusted Basis on February 2, 2024 |
globenewswire.com |
2024-01-31 13:15:00 |
Czytaj oryginał (ang.) |
| BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy |
Westport, CT, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced a workforce reduction, intended to reduce annual cash burn by 50%. The Company is reducing its internal workforce, which is expected to be completed by January 31. The Company is also shifting its business model and seeks to partner with organizations for sales distribution and clinical support of its PURE EP™ Platform. |
globenewswire.com |
2024-01-30 10:30:00 |
Czytaj oryginał (ang.) |
| BioSig Issues Letter to Shareholders Detailing Technology Innovations and Strategic Focus for 2024 |
Westport, CT, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today issued its 2023 letter to shareholders to recap recent achievements and offer insights about the year ahead. |
globenewswire.com |
2023-12-06 16:20:00 |
Czytaj oryginał (ang.) |
| BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules |
Westport, CT, Nov. 13, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 6,996,922 shares of its common stock, Series A warrants to purchase up to 6,996,922 shares of common stock and Series B warrants to purchase up to 6,996,922 shares of common stock, at a purchase price of $0.3573 per share of common stock and associated warrants. |
globenewswire.com |
2023-11-13 18:30:00 |
Czytaj oryginał (ang.) |
| BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules |
Westport, CT, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Westport, CT, Nov. 9, 2023 -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 6,996,922 shares of its common stock, Series A warrants to purchase up to 6,996,922 shares of common stock and Series B warrants to purchase up to 6,996,922 shares of common stock, at a purchase price of $0.3573 per share of common stock and associated warrants, in a registered direct offering priced at-the-market under Nasdaq rules. |
globenewswire.com |
2023-11-09 10:00:00 |
Czytaj oryginał (ang.) |
| BioSig Adds Five New Patent Awards to 100+ Total Patent Portfolio Covering Digital Signal Processing Technology and AI |
IP portfolio includes U.S. and worldwide utility and design patents and pending applications in the U.S., Europe, and Asia-Pacific IP portfolio includes U.S. and worldwide utility and design patents and pending applications in the U.S., Europe, and Asia-Pacific |
globenewswire.com |
2023-11-01 10:30:00 |
Czytaj oryginał (ang.) |
| BioSig (BSGM) Grows in Arrhythmia Care With Subscription Model |
BioSig's (BSGM) subscription model for PURE EP provides electrophysiologists and cardiology departments with flexibility. |
zacks.com |
2023-08-25 15:17:06 |
Czytaj oryginał (ang.) |
| BioSig AI Sciences Achieves Infrastructure and Technology progress in Development of Generative AI Platform for Hospitals |
Westport, CT, Aug. 24, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today is providing an update since the launch of BioSig's established technology team with external partners and collaborators to advance the research and development of an artificial intelligence (“AI”) medical device platform. |
globenewswire.com |
2023-08-24 14:30:00 |
Czytaj oryginał (ang.) |
| BioSig Introduces New Subscription Model for PURE EP™ Platform, Offering Quicker Access to Latest Features, Customizations |
Cleveland Clinic, the #1 heart center in the Nation, signs on as first subscriber to receive latest software advancements in intracardiac signal visualization Cleveland Clinic, the #1 heart center in the Nation, signs on as first subscriber to receive latest software advancements in intracardiac signal visualization |
globenewswire.com |
2023-08-23 12:30:00 |
Czytaj oryginał (ang.) |